Bank Of America Corp Uro Gen Pharma Ltd. Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Bank Of America Corp holds 53,063 shares of URGN stock, worth $842,640. This represents 0.0% of its overall portfolio holdings.

Number of Shares

53,063

Previous 71,664 25.96%

Holding current value

$842,640

Previous $1.07 Million 25.98%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$13.81 - $19.33 $256,879 - $359,557	-18,601 Reduced 25.96%	53,063 $795,000
Q4 2023 Feb 14, 2024	BUY	$10.87 - $15.93 $435,723 - $638,554	40,085 Added 126.94%	71,664 $1.07 Million
Q2 2023 Aug 14, 2023	SELL	$8.75 - $14.29 $866,565 - $1.42 Million	-99,036 Reduced 75.82%	31,579 $326,000
Q1 2023 May 12, 2023	BUY	$7.99 - $11.02 $81,010 - $111,731	10,139 Added 8.42%	130,615 $1.21 Million
Q4 2022 Feb 10, 2023	BUY	$7.55 - $11.9 $3,050 - $4,807	404 Added 0.34%	120,476 $1.07 Million

Q3 2022 Nov 14, 2022	SELL	$7.21 - $9.41 $25,487 - $33,264	-3,535 Reduced 2.86%	120,072 $999,000
Q2 2022 Aug 12, 2022	SELL	$5.12 - $8.74 $24,115 - $41,165	-4,710 Reduced 3.67%	123,607 $1.01 Million
Q1 2022 May 16, 2022	BUY	$5.92 - $9.73 $515,365 - $847,045	87,055 Added 210.98%	128,317 $1.12 Million
Q4 2021 Feb 08, 2022	BUY	$9.03 - $19.13 $42,612 - $90,274	4,719 Added 12.91%	41,262 $392,000
Q3 2021 Nov 15, 2021	SELL	$14.31 - $18.39 $759,746 - $976,361	-53,092 Reduced 59.23%	36,543 $614,000
Q2 2021 Sep 13, 2021	BUY	$15.2 - $20.94 $1.36 Million - $1.88 Million	89,635 New	89,635 $1.37 Million

Others Institutions Holding URGN

# of Institutions

113

Shares Held

24M

Call Options Held

46.9K

Put Options Held

44.3K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $361M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Uro Gen Pharma Ltd. Transaction History